Aprea Therapeutics
APRE
50 hedge funds and large institutions have $468M invested in Aprea Therapeutics in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
28% more funds holding
Funds holding: 39 → 50 (+11)
0.12% more ownership
Funds ownership: 3.08% → 3.2% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $591M → $468M (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.4M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$2.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.91M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$1.77M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$21.5M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.22M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$688K |
| 4 |
Morgan Stanley
New York
|
-$473K |
| 5 |
Millennium Management
New York
|
-$291K |
APRE Hedge Fund Activity: Q1 2020 in Review
50 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2020, worth a combined $468M — down 21% from $591M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new APRE positions and 4 closed out — a net gain of 11 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $32.4M. The largest seller was Janus Henderson Group, cutting an estimated $21.5M.
- 50 institutional investors held Aprea Therapeutics (APRE) as of Q1 2020, up from 39 in Q4 2019.
- Funds reported $468M of Aprea Therapeutics stock for Q1 2020, down 21% quarter-over-quarter.
- 15 funds opened new Aprea Therapeutics positions in Q1 2020 and 4 closed out, a net change of +11 holders.
- The largest Aprea Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $32.4M added.
- The largest Aprea Therapeutics seller in Q1 2020 was Janus Henderson Group, an estimated $21.5M sold.
Based on aggregated 13F filings for Q1 2020.